59
Pharma & HealthcareHold
UTI Healthcare
UTI · Direct–Growth · rank #5 of 19 by Smart Score
Data updated
Trailing returns
1 Year
22.0%
+21.3% vs index
3 Years
23.1%
+11.5% vs index
5 Years
17.7%
+7.6% vs index
Since launch
16.5%
Year-by-year performance
2021
+20.4%-10.3% vs index
2022
-11.3%-15.1% vs index
2023
+39.6%+13.0% vs index
2024
+44.3%+28.6% vs index
2025
-2.2%-9.8% vs index
2026
+24.0%+23.1% vs index
Why this score
UTI Healthcare scores 59/100 — #5 of 19 Pharma & Healthcare fund (Hold). It stands out for 3y return and 5y return — beating 71% of peers on 3y return. The main drag is its expense ratio (better than only 19% of peers).
Each bar shows the fund's percentile vs Pharma & Healthcare peers — a longer bar beats more of the category.
3Y return23.06% · 71st percentile in category
5Y return17.74% · 65th percentile in category
Expense ratio1.34% · 19th percentile in category
Sharpe ratio1.06 · 72nd percentile in category
Sortino ratio1.71 · 80th percentile in category
Volatility16.04 · 34th percentile in category
Top holdings
1.Sun Pharmaceutical Industries Ltd7.44%
2.Divi's Laboratories Ltd6.46%
3.Dr. Reddy's Laboratories Ltd5.78%
4.Ajanta Pharma Ltd4.29%
5.Max Healthcare Institute Ltd4.2%
46 disclosed equity positions · portfolio as of Oct 2026 · weights are % of total corpus.